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MicroRNAs are small non-coding RNAs of around 22
nucleotides that post-transcriptionally regulate gene
expression. MicroRNAs have important functions in
embryogenesis, hematapoiesis and carcinogenesis. Virally
encoded microRNAs have been identified in EBV and
KSHV and recent data suggest a role for both viral and
host microRNAs in pathogenesis. We have developed a
custom microarray to detect expression of all human and
viral microRNAs. Probes are 60 mer oligonucleotides con-
taining a 40 nucleotide non genomic linker sequence.
Four replicates of each probe are represented on the array
and eight arrays are printed on each slide. The arrays are
printed by Agilent ensuring excellent quality control. We
have used this array to profile viral and host microRNAs
in KSHV in primary effusion lymphoma (PEL) cells
infected with KSHV alone or KSHV and EBV, and in KSHV
infected and uninfected endothelial cells. The effect of
KSHV reactivation on viral and host microRNA expression
was determined by induction of viral replication by an
adenovirus vector expressing KSHV ORF 50, the master
switch of lytic replication.
KSHV encoded microRNAs were detected in PEL cell lines
during latency and levels of expression did not substan-
tially change after reactivation. The EBV co-infected PEL
cell lines also expressed high levels of the EBV encoded
BART2 microRNAs but not the BHRF1–3 microRNAs.
Interestingly, KSHV reactivation caused an increase of EBV
encoded microRNAs. PEL lines display a unique cellular
microRNA expression pattern which may contribute to
their post-germinal center arrested phenotype.
In addition, we detected for the first time viral and cellular
microRNA expression patterns in two different endothe-
lial cell lines (TIVE and SLK) latently infected with KSHV.
KSHV infection leads to a marked induction of human
microRNA expression including several microRNAs with
known roles in carcinogenesis. Ongoing studies include
microRNA profiling of EBV infected B cells and lym-
phoma cell lines as well as KSHV infected primary B cells.
Viral microRNAs are expressed in infected cells and likely
modulate both viral and host genes relevant to lymphom-
agenesis. EBV and KSHV infection also up-regulate expres-
sion of host microRNAs previously shown to play a role in
tumorogenesis.
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